Oncology drug discovery: planning a turnaround.

We have made remarkable progress in our understanding of the pathophysiology of cancer. This improved understanding has resulted in increasingly effective targeted therapies that are better tolerated than conventional cytotoxic agents and even curative in some patients. Unfortunately, the success rate of drug approval has been limited, and therapeutic improvements have been marginal, with too few exceptions. In this article, we review the current approach to oncology drug discovery and development, identify areas in need of improvement, and propose strategies to improve patient outcomes. We also suggest future directions that may improve the quality of preclinical and early clinical drug evaluation, which could lead to higher approval rates of anticancer drugs.

[1]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[2]  Colleen V. Chien,et al.  Managing innovation: university-industry partnerships and the licensing of the Harvard mouse , 2004, Nature Biotechnology.

[3]  S. Liou,et al.  Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Haber,et al.  Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. , 2005, Cold Spring Harbor symposia on quantitative biology.

[5]  G. Schwartz,et al.  Targeting Checkpoint Kinase 1 in Cancer Therapeutics , 2007, Clinical Cancer Research.

[6]  Alexander Kamb,et al.  Why is cancer drug discovery so difficult? , 2007, Nature Reviews Drug Discovery.

[7]  Lee Harland,et al.  Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery , 2009, Nature Reviews Drug Discovery.

[8]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[9]  C. Kenific,et al.  Down‐regulation of the Notch pathway mediated by a γ‐secretase inhibitor induces anti‐tumour effects in mouse models of T‐cell leukaemia , 2009, British journal of pharmacology.

[10]  F. D. de Sauvage,et al.  Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. , 2009, Trends in pharmacological sciences.

[11]  Sridhar Ramaswamy,et al.  Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells , 2009, Cell.

[12]  C. Tralau-Stewart,et al.  Drug discovery: new models for industry-academic partnerships. , 2009, Drug discovery today.

[13]  Paul Workman,et al.  Drugging the PI3 kinome: from chemical tools to drugs in the clinic. , 2010, Cancer research.

[14]  Ian Collins,et al.  Probing the Probes: Fitness Factors For Small Molecule Tools , 2010, Chemistry & biology.

[15]  L. Chin,et al.  Non-germline genetically engineered mouse models for translational cancer research , 2010, Nature Reviews Cancer.

[16]  John E. Harlan,et al.  Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor , 2011, Clinical Cancer Research.

[17]  René Bernards,et al.  Taming the dragon: genomic biomarkers to individualize the treatment of cancer , 2011, Nature Medicine.

[18]  J. McCarter,et al.  STK33 kinase activity is nonessential in KRAS-dependent cancer cells. , 2011, Cancer research.

[19]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[20]  W. Pao,et al.  How genetically engineered mouse tumor models provide insights into human cancers. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Licinio,et al.  Improving the efficacy of translational medicine by optimally integrating health care, academia and industry , 2011, Nature Medicine.

[22]  Scott H. Kaufmann,et al.  Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro , 2012, Clinical Cancer Research.

[23]  G. Dranoff,et al.  Experimental mouse tumour models: what can be learnt about human cancer immunology? , 2011, Nature Reviews Immunology.

[24]  Mallika Singh,et al.  Modeling and predicting clinical efficacy for drugs targeting the tumor milieu , 2012, Nature Biotechnology.

[25]  Nathan T. Ross,et al.  STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability , 2012, Proceedings of the National Academy of Sciences.

[26]  Nathan T. Ross,et al.  A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells , 2012, ACS medicinal chemistry letters.

[27]  Daniel Q. Bach,et al.  Trends in Personalized Therapies in Oncology: The (Venture) Capitalist’s Perspective , 2012, Journal of personalized medicine.

[28]  Andrew L. Kung,et al.  A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response , 2012, Nature.

[29]  I. Khanna,et al.  Drug discovery in pharmaceutical industry: productivity challenges and trends. , 2012, Drug discovery today.

[30]  J. Settleman,et al.  Mechanisms of acquired resistance to targeted cancer therapies. , 2012, Future oncology.

[31]  D. Berry.  Adaptive clinical trials in oncology , 2012, Nature Reviews Clinical Oncology.

[32]  Aik Choon Tan,et al.  Patient-derived tumour xenografts as models for oncology drug development , 2012, Nature Reviews Clinical Oncology.

[33]  S. Fesik,et al.  Abstract 1813: Evaluation of TBK1 as a novel cancer target in the K-Ras pathway , 2012 .

[34]  C. Swanton.  Intratumor heterogeneity: evolution through space and time. , 2012, Cancer research.

[35]  E. Richard Gold,et al.  Recalibrating Intellectual Property Rights to Enhance Translational Research Collaborations , 2012, Science Translational Medicine.

[36]  A. Fojo,et al.  Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale , 2012, Clinical Cancer Research.

[37]  Funda Meric-Bernstam,et al.  Overcoming implementation challenges of personalized cancer therapy , 2012, Nature Reviews Clinical Oncology.

[38]  C. Sigman,et al.  Cancer biomarkers: selecting the right drug for the right patient , 2012, Nature Reviews Drug Discovery.

[39]  Promoting drug discovery by collaborative innovation: a novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare. , 2012, Drug discovery today.

[40]  David R Parkinson,et al.  Making Personalized Cancer Medicine a Reality: Challenges and Opportunities in the Development of Biomarkers and Companion Diagnostics , 2012, Clinical Cancer Research.

[41]  Hakim Djaballah.  Editorial. Random RNAi screening data analysis: a call for standardization. , 2012, Combinatorial chemistry & high throughput screening.

[42]  W. Kaelin,et al.  Use and Abuse of RNAi to Study Mammalian Gene Function , 2012, Science.

[43]  Razelle Kurzrock,et al.  Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative , 2012, Clinical Cancer Research.

[44]  Ryohei Katayama,et al.  Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. , 2013, Cancer research.

[45]  Laura E. MacConaill,et al.  Existing and emerging technologies for tumor genomic profiling. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[47]  J. Mendelsohn.  Personalizing oncology: perspectives and prospects. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  E. Lander,et al.  Lessons from the Cancer Genome , 2013, Cell.

[49]  Levi A Garraway,et al.  Genomics-driven oncology: framework for an emerging paradigm. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  A. Bardelli,et al.  Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET , 2013, Clinical Cancer Research.

[51]  R. Sullivan,et al.  Resistance to BRAF-targeted therapy in melanoma. , 2013, European journal of cancer.

[52]  T. Yap,et al.  Development of therapeutic combinations targeting major cancer signaling pathways. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  Richard Simon,et al.  Implementing personalized cancer genomics in clinical trials , 2013, Nature Reviews Drug Discovery.

[54]  M. Loda,et al.  A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer , 2013, Nature Genetics.